Evidence map›Paper›PMID 33580813›Full record

ArticlePsychopharmacology2021

Long acting aripiprazole influences cognitive functions in recent onset schizophrenia.

Vjekoslav Peitl, Mario Štefanović, Ivona Orlović, Jelena Culej, Ana Rendulić, Krunoslav Matešić, Dalibor Karlović

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Vjekoslav PeitlDepartment of Psychiatry, University Hospital Centre Sestre Milosrdnice, Zagreb, Croatia. vjekoslav.peitl@gmail.com.ORCID http://orcid.org/0000-0003-4163-6411
Mario ŠtefanovićClinical Department of Chemistry, University Hospital Centre Sestre Milosrdnice, Zagreb, Croatia.
Ivona OrlovićDepartment of Psychiatry, University Hospital Centre Sestre Milosrdnice, Zagreb, Croatia.
Jelena CulejClinical Department of Chemistry, University Hospital Centre Sestre Milosrdnice, Zagreb, Croatia.
Ana RendulićDepartment of Psychiatry, University Hospital Centre Sestre Milosrdnice, Zagreb, Croatia.
Krunoslav MatešićCatholic University of Croatia, Ilica 242, 10000, Zagreb, Croatia.
Dalibor KarlovićDepartment of Psychiatry, University Hospital Centre Sestre Milosrdnice, Zagreb, Croatia.
Catholic University of Croatia · HRSisters of Charity Hospital · HRUniversity Hospital Centre Zagreb · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleBeneficial effects of aripiprazole on cognition in schizophrenia have been previously reported, but not in recent onset schizophrenia. Cognitive impairments have also been associated with catechol-O-methyltransferase (COMT), methylenetetrahydrofolate reductase (MTHFR), and serotonin transporter (SERT) gene polymorphisms which were earlier implicated in the pathophysiology of schizophrenia.

objectivesThis study examined the short-term influence of aripiprazole long-acting injectable (LAI) as well as of COMT, MTHFR, and SERT gene polymorphisms and their interactions on clinical features and cognitive functions in inpatients with recent onset schizophrenia.

methodsThis study included 98 inpatients suffering from recent onset schizophrenia diagnosed according to DSM-5 criteria. Three months after initiating aripiprazole LAI, the severity of symptoms was assessed by the Positive and Negative Syndrome Scale (PANSS), while cognitive functions were measured by 5-KOG test for cognition. Genotypes of SERT, MTHFR, and COMT gene were determined by different polymerase chain reaction (PCR) methods.

resultsThree-month aripiprazole LAI treatment was associated with a statistically significant change of PANSS total (p<0.001) and subscale scores as well as cognitive parameters of delayed recall (p<0.03), attention (p<0.01), and executive functions in the form of less perseverations (p<0.03), without influencing other examined cognitive functions. However, it significantly influenced composite cognitive score (p<0.02). In regard to the investigated genetic polymorphisms, we established a positive association between the COMT polymorphism (M/M allele carriers) and attention (p<0.01). Additionally, we also established a positive association between the COMT - MTHFR interaction and attention (p<0.02), as well as perseveration item belonging to executive functions (p<0.01). Two other investigated polymorphisms (MTHFR and SERT) were not significantly associated with cognitive indices. Investigated genetic polymorphisms and their interactions were not associated with PANSS scores.

conclusionsOur findings suggest that aripiprazole LAI improves individual cognitive functions in recent onset schizophrenia. Investigated COMT polymorphism (Met/Met genotype), as well as the COMT-MTHFR interaction, were positively associated with attention and executive functioning (perseveration), potentially implying COMT's biomarker potential in terms of cognition in schizophrenia.

Indexed as

AdolescentAdultAllelesAripiprazoleAttentionCatechol O-MethyltransferaseCognitionExecutive FunctionFemaleGenotypeHumansMaleMethylenetetrahydrofolate Reductase (NADPH2)Middle AgedPolymorphism, GeneticSchizophreniaAripiprazoleCatechol O-MethyltransferaseMethylenetetrahydrofolate Reductase (NADPH2)AripiprazoleCognitionPolymorphism, GeneticSchizophrenia

Identifiers

PMID33580813
OpenAlexW3126729809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.